Pediatric Hematopoietic Stem Cell Transplant Fellowship Curriculum

The following table summarizes the time commitment allotted for each rotation to meet the specific goals and objectives on the fellowship:

RotationTime
Inpatient Service (IP)20 weeks
Outpatient Service (OP)16 weeks*
Research (R)12 weeks
Vacation (PTO)4 weeks
Total52 weeks

*2 weeks of electives may be taken if interest is made. Electives include: Radiation Oncology, Transfusion Medicine, HLA Lab, or Stem Cell Lab

Additionally, all fellows would have a weekly continuity clinic, which will consist of a variety of patients accrued over the course of the year.

All fellows will be expected to participate in the Hematology/Oncology education opportunities as well as develop a clinical research project under close mentorship by a faculty member.

Fellows are expected to work one weekend during each 4-week block.

Sample Block Schedule for Pediatric HSCT Fellowship:

 Block 1Block 2Block 3Block 4Block 5Block 6Block 7Block 8Block 9Block 10Block 11Block 12Block 13
Week 1IPIPIPPTOIPOPOPOPOPIPIPPTOOP
Week 2OPOPIPIPIPIPIPIPIPIPIPIPR
Week 3RROPRRIPIPRRRRIPIP
Week 4RROPOPOPOPOPPTOPTOOPOPOPR

Schedules can be individualized based on particular experience/interest of specific candidates

Additionally, our program provides opportunities to collaborate with colleagues at Mayo Clinic whom PCH shares a joint-FACT accreditation. At PCH we lead the state of Arizona in the number of transplants performed annually in pediatrics and were the first center in the state to offer chimeric antigen receptor T-cell (CAR-T) therapy.

Procedures

ProceduresNumber of Procedures
Bone Marrow HarvestsExpect 5 per year
Bone Marrow Aspirates/ BiopsiesExpect 5 per year
Lumbar PuncturesExpect 5 per year
Stem Cell Transplants/Cellular Therapy AdministrationExpect Fellow to oversee 15 during the year

All Bone Marrow Transplant (BMT) fellows will be required to do the following procedures: In 2019, the BMT Program at Phoenix Children’s Hospital performed the following: 47 hematopoietic stem cell transplants (HSCT) and 8 chimeric antigen receptor T-cell (CAR-T) cellular therapies. Within these 47 HSCT, 8 were from sibling donor bone marrow harvests (Figure 1).

Figure 1:

BTM Cellular Therapy Program Volume Dashboard Image

All malignant patients and some non-malignant patients require bone marrow aspirates and/or biopsies following HSCT. High risk malignant patients require a total of 6 bone marrow aspirates within the first-year post HSCT. Additionally, patients with central nervous system disease prior to undergoing HSCT require screening lumbar punctures following HSCT (monthly for 3-6 months). This will provide plenty of opportunity for a training fellow to practice and sign off on procedures. Please see image below for full specifications from the BMT/Cellular therapy volume.